Search results | lymphoma

Reports

Lymphoma Partnering

The Lymphoma Partnering 2007-2012 provides understanding and access to the lymphoma partnering deals and agreements entered into by the worlds leading healthcare companies

Brain Cancer Partnering

The Brain Cancer Partnering provides understanding and access to the brain cancer partnering deals and agreements entered into by the worlds leading healthcare companies.

Liver Cancer Partnering

The Liver Cancer Partnering provides understanding and access to the liver cancer partnering deals and agreements entered into by the worlds leading healthcare companies

Insights

Pharmacyclics: Partnering activity 2009-2014

Pharmacyclics, listed as a new big biotech entrant in 2014, works to improve the lives of cancer affected patients by entering into strategic partnering deals to support its product pipeline.

Pharmacyclics: The talk of the partnering town

Pharmacyclics is a biopharmaceutical company founded in April 1991 discovering and developing medications to treat and alleviate the suffering of oncology patients.

Industry analysis: Cancer monoclonal antibody partnering on the rise

Monoclonal antibodies are developed to be very selective in targeting cells. This is why they have come to be an indispensable research tool in cancer treatment being able to specifically target tumor cells.

Seattle Genetics: Empowering monoclonal antibodies

Seattle Genetics is a biotech company developing and commercializing antibody-based therapeutics to improve the lives of people living with cancer.

Seattle Genetics : Biotech industry partnering activity 2009-2014

Seattle Genetics, a successful big biotech industry headquartered in Seattle, focuses its effort on advancing antibody drug conjugate technology targeted toward cancer treatment.

Market research analysis: Monoclonal antibody partnering

A recent market research analysis of monoclonal antibody partnering has shown a high interest in partnering deals involving monoclonal antibody technology in the past few years

Spectrum Pharmaceuticals: Partnering activity 2009-2014

Spectrum Pharmaceuticals, headquartered in the United States, showcases in the top 50 big biotech companies.

Spectrum Pharmaceuticals: M&A activity 2009-2014

Spectrum Pharmaceuticals is a big biotech company focused on late stage drugs.

Spectrum Pharmaceuticals: Where partnering IS the business model

Spectrum Pharmaceuticals is a biotechnology company providing key oncology and haematology products for patients around the world.

Celgene

Celgene is a top pharmaceutical company, incorporated in Delaware and headquartered in Summit, New Jersey

Events

Sorry, your search returned no results.


Deals

EMD Serono and Pfizer in co-promotion agreement for Xalkori

EMD Serono has begun co-promoting Pfizer’s anaplastic lymphoma kinase (ALK) inhibitor XALKORI (crizotinib) as part of its global strategic alliance with Pfizer.

Eisai returns EZH2 program, including EPZ-6438 to Epizyme

Epizyme has reacquired global rights to its EZH2 program, including EPZ-6438, from its partner Eisai

Teva enters into pharma licensing deal with Eagle Pharmaceuticals for cancer drug

Teva Pharmaceutical Industries has entered into a $120 million pharma licensing agreement that will allow it to distribute and promote a competitor to its own cancer drug, Eagle Pharmaceuticals EP-3102.

BMS and Seattle evaluate Adcetris and Opdivo combination

Seattle Genetics and Bristol-Myers Squibb have entered into a clinical trial collaboration agreement to evaluate the investigational combination of Seattle Genetics’ antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) and Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in two planned Phase 1/2 clinical trials

Cell Medica series B brings in $78 million

Cell Medica announced the closing of a £50 million Series B investment round with participation from Imperial Innovations, Invesco Perpetual and Woodford Investment Management

Pharmacyclics forms an pharma alliance with Roche

Pharmacyclics has entered into a pharma alliance agreement with Roche to evaluate the safety, tolerability and preliminary efficacy of IMBRUVICA (ibrutinib)in combination with GAZYVA (obinutuzumab).

BMS and Janssen signs a pharma alliance for cancer treatment

BMS, Pharmacyclics and Janssen R&D have started a pharma alliance for Opdivo and Imbruvica evaluation.

Big biotech, Spectrum Pharma and CASI Pharma signed a licensing agreement

China-based, CASI has signed a licensing agreement with big biotech, Spectrum Pharma’s for its products: Zevalin, Marqibo and Melphalan.

Denovo Biopharma has acquired enzastaurin from Eli Lilly

Denovo Biopharma has acquired enzastaurin, a late-stage oncology drug, from Eli Lilly and Company.

Abbvie strikes a pharma alliance with Infinity Pharma

Infinity Pharmaceuticals and AbbVie have entered into a global pharma alliance to develop and commercialize duvelisib (IPI-145), Infinity’s oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, for the treatment of patients with cancer.